Home / Business and Economy / GoodRx Beats Revenue Targets Amid Sales Dip
GoodRx Beats Revenue Targets Amid Sales Dip
6 Aug
Summary
- GoodRx exceeded Q2 revenue expectations, reporting $200.4 million.
- Full-year revenue guidance was raised, surpassing analyst estimates.
- The company's revenue experienced a 1.3% year-on-year decline.
Healthcare technology firm GoodRx reported its Q2 CY2026 financial results, surpassing market revenue expectations. The company achieved $200.4 million in revenue, a slight 1.3% decrease from the previous year, but this figure exceeded analyst estimates by 3.5%.
GoodRx has also improved its financial outlook, raising its full-year revenue guidance to a midpoint of $797.5 million, which is 2.8% above prior analyst consensus. Adjusted earnings per share were in line with expectations at $0.08, and adjusted EBITDA also beat estimates.
However, the company's long-term growth trajectory shows mediocrity, with annualized revenue growth of 4.5% over five years falling short of benchmarks. Recent performance indicates demand has slowed, with revenue remaining flat for the last two years.
Looking forward, sell-side analysts anticipate flat revenue over the next 12 months, suggesting new products may not yet significantly boost top-line performance. The company's operating margin and free cash flow margin have also seen a decline compared to the same quarter last year.
